PsychiatryAbbVie
AbbVie Reports Positive Phase 2 EMPOWER Trial Results for Emraclidine in Schizophrenia
BMI
Biotechnology Media Insights
Editorial Team · July 10, 2025
AbbVie announces positive Phase 2 EMPOWER trial results showing emraclidine significantly reduces schizophrenia symptoms without dopamine receptor blockade.
AbbVie today announced positive results from the Phase 2 EMPOWER trial evaluating emraclidine in patients with acute schizophrenia. The trial met its primary endpoint, demonstrating a significant reduction in Positive and Negative Syndrome Scale (PANSS) total score compared to placebo at week 6.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.